Zacks Investment Research
05 Aug 2026, 19:50 UTC · 1h ago
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
05 Aug 2026, 19:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Harmony Biosciences (HRMY) reported Q2 2026 earnings of $1.28 per share and revenue of $261.28 million, beating analyst estimates of $0.97 EPS and $253 million in revenue. — Strong earnings and revenue beats typically drive immediate positive price action, as evidenced by the stock's 8.9% gain following the report.
+0.60The average patient count for Harmony's lead drug, Wakix, increased by 450 sequentially to 8,950. — Sustained growth in the patient base for the primary revenue driver indicates strong product demand and future growth scalability.
+0.40Harmony reported favorable Phase I data for its orexin-2 receptor agonist candidate BP-205, showing it was safe, well-tolerated, and supports once-daily dosing. — Positive early-stage clinical data for a pipeline drug reduces binary risk and suggests potential for future portfolio diversification.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Cost of products sold rose to 24.2% of revenue from 19% year-over-year, primarily due to new royalties from the Novitium license agreement. — Increased cost of goods sold compresses gross margins, though it is tied to a strategic licensing expansion.
-0.20Which stocks this story touches
The company reported an earnings beat, revenue growth of 30%, and positive phase I data for BP-205, leading to an 8.9% share price increase.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
1h ago
